Charles River Laboratories International, Inc.

Q3 2026
Speakers

Nov 4, 2026 · 76 min

SECTION UNKNOWN · Q&A BOUNDARY NOT IDENTIFIEDKeys: / search · Space play · ←→ ±10s · [] sections

Transcript

Speaker 0

Unverified voice label

Ladies and gentlemen, thank you for standing by. Welcome to the Charles River Laboratory's Third Quarter 2026 Earnings Conference Call. This conference call is being recorded. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during this period, you will need to press star one on your telephone keypad.

If you would like to remove yourself from the cube, please press star two. Lastly, if you should need any operator assistance today, please press star zero.
?I would now like to turn the conference over to our host, Mr. Todd Spencer, Vice President Investor Relations. Please go ahead,

Passages & reports (4)
  • Ladies and gentlemen, thank you for standing by. Welcome to the Charles River Laboratory's…
  • you will need to press star one on your telephone keypad. If you would like to remove your…
  • I
  • would now like to turn the conference over to our host, Mr. Todd Spencer, Vice President I…

Speaker unclear

?sir.

Passages & reports (1)
  • sir.

Speaker 1

Unverified voice label

Good morning, and welcome to Charles River Laboratory's third quarter 2026 Earnings Conference Column webcast. This morning, I am pleased to be joined by Birgit Gershik, our Chief Executive Officer, and by Glenn Coleman, our Executive Vice President and Chief Financial Officer. They will comment on our results for the third quarter of 2026, as well as our financial guidance. Following the presentation, they will respond to questions.

There is a slide presentation associated with today's remarks, which will be posted on the Investor Relations section of our website at IR.criver.com. A webcast replay of this call will be available beginning approximately two
hours after the call today and can also be accessed on the Investor Relations website. ?The replay will be available through next quarter's conference ?call. I'd like to remind you of our safe harbor.

All remarks that we make about future expectations, plans, and prospects for the company constitute forward looking statements under federal securities law, including the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated.
During this call, we will primarily discuss non GAP financial measures, which we believe help investors gain a meaningful understanding of our core operating results and guidance. ?

The
non GAP financial measures are not meant to be considered superior to or a substitute for results prepared in accordance with GAAP. In accordance with Regulation G, you can find the comparable GAAP measures and the reconciliations on the investor relations section of our website. ?I will now turn the call over to Birgit Gershik.

Passages & reports (12)
  • Good morning, and welcome to Charles River Laboratory's third quarter 2026 Earnings Confer…
  • 2026, as well as our financial guidance. Following the presentation, they will respond to …
  • hours after the call today and can also be accessed on the Investor Relations website.
  • The
  • replay will be available through next quarter's conference
  • call.
  • I'd like to remind you of our safe harbor. All remarks that we make about future expectati…
  • During this call, we will primarily discuss non GAP financial measures, which we believe h…
  • The
  • non GAP financial measures are not meant to be considered superior to or a substitute for …
  • I
  • will now turn the call over to Birgit Gershik.

Speaker 2

Unverified voice label

Thank you, Todd, and good morning. We are pleased today to report another solid quarter with revenue and non-GAAP earnings per share that exceeded our prior outlook, continued momentum in the improving biopharmaceutical demand environment, and additional progress towards the execution of our pathway to purpose strategic vision. It was wonderful to see many of you at our Investor Day just over one month ago, and I hope that you found it to be an informative discussion about our strategic initiatives designed to enhance our operational excellence and strengthen our scientific leadership as well as our future growth drivers and long term financial targets.

As I mentioned, our focus is to simplify the company and move faster, invest where we can win, and continue to lead as a scientific partner of choice for the critical work that our
clients do. By executing these goals, we believe it will translate into higher growth and operating margins and drive long term shareholder value creation. We have made meaningful progress in recent months on initiatives to support our pathway to purpose strategy, which includes working to modernize our company and the industry, strengthening our world-class scientific portfolio, and offering a customized client-centric approach to drive growth.

I will now provide you with highlights that demonstrate some of this progress
as well as our third quarter performance. We were encouraged by the acceleration of our revenue growth rate in the third quarter as we had anticipated, including solid mid single digit organic growth in the DSA segment and high single digit organic growth in the manufacturing segment. The solid DSA performance was supported by a net book to bill of one point zero nine times in the third quarter, which marks the fourth consecutive quarter that the net book to bill has been above one times, averaging approximately 1.1 times over this period.

Both the third quarter and trailing 12 months DSA booking performance were consistent with the levels needed to support our long term financial targets of five to seven percent growth in the DSA segment. With the C DMO business having been divested for a
full quarter, we were also pleased to clearly see the underlying growth and and margin trends emerge for the manufacturing segment and believe the outlook remains favorable for our comprehensive manufacturing quality control testing solutions.

We expect these collective trends to
support the improvement to MIP single digit organic growth for the company in the second half of this year, as well as the projected margin improvements. To enhance our ability to take advantage of improving domain, we are also working on our modernization efforts to drive greater efficiency, including through our Create the Future Transformation program. As an example, in July, we implemented a fully automated manufacturing suite for our end-o-safe endotoxin cartridge technology to increase cartridge production capacity, strengthen manufacturing controls, and enhance digital traceability.

This upgrade improves quality and labor productivity and also increases cartridge production capacity by 14%. Also in our manufacturing segment, we partnered with
Autolomus to launch Apollo Orchestrate to digitize laboratory workflows and enhance client connectivity. This is a new capability for our Apollo platform, which will transform laboratory execution systems, increase efficiency, and provide greater transparency and collaboration for clients. These are two examples of progress in our Create the Future Transformation program, which is expected to generate over $300 million in cumulative savings over the next four years and will be a key component to drive meaningful operating margin improvement in 2027 and beyond.

We have also taken steps to continue to strengthen our scientific capabilities. We announced a collaboration with the FDA to validate preclinical screening tools to
quantify and rank the abuse potential of new drugs. This collaboration is aimed at approving public health by helping to ensure the safety of drugs.

Passages & reports (16)
  • Thank you, Todd, and good morning. We are pleased today to report another solid quarter wi…
  • to purpose strategic vision. It was wonderful to see many of you at our Investor Day just …
  • scientific leadership as well as our future growth drivers and long term financial targets…
  • clients do. By executing these goals, we believe it will translate into higher growth and …
  • strategy, which includes working to modernize our company and the industry, strengthening …
  • as well as our third quarter performance. We were encouraged by the acceleration of our re…
  • segment. The solid DSA performance was supported by a net book to bill of one point zero n…
  • period. Both the third quarter and trailing 12 months DSA booking performance were consist…
  • full quarter, we were also pleased to clearly see the underlying growth and and margin tre…
  • support the improvement to MIP single digit organic growth for the company in the second h…
  • greater efficiency, including through our Create the Future Transformation program. As an …
  • manufacturing controls, and enhance digital traceability. This upgrade improves quality an…
  • Autolomus to launch Apollo Orchestrate to digitize laboratory workflows and enhance client…
  • transparency and collaboration for clients. These are two examples of progress in our Crea…
  • meaningful operating margin improvement in 2027 and beyond. We have also taken steps to co…
  • quantify and rank the abuse potential of new drugs. This collaboration is aimed at approvi…

As part of our efforts to further advance our alternative methods advancement project initiative, or AMAP, we also introduced a new Rapid Cell Banking program designed to significantly accelerate product release timelines in the biologics testing business. By combining rapid cell bank and release packages with advanced characterization using in vitro next generation sequencing capabilities, we will be able to reduce cell bank production timelines by 40% versus the industry standard of 20 weeks, enabling clients who develop advanced therapies to reach key milestones and bring their innovative treatments to patients faster.

In addition, we continue to pioneer in the space of virtual control groups or VCGs to selectively reduce animal use where scientifically
appropriate. Last week we announced that our VCG database and methodology will now be used in a GOP compliant safety assessment study for Ibsen, a biopharmaceutical client. This moves the use of VCGs from concept to regulatory submission.

Passages & reports (4)
  • As part of our efforts to further advance our alternative methods advancement project init…
  • By combining rapid cell bank and release packages with advanced characterization using in …
  • develop advanced therapies to reach key milestones and bring their innovative treatments t…
  • appropriate. Last week we announced that our VCG database and methodology will now be used…

The execution of these kinds of initiatives is already benefiting us with clients because of our client-centric approach and the value that we provide to our clients through the global breadth and scientific depth that we are able to offer, we recently extended our relationship with a top 10 biopharmaceutical company to serve as a primary strategic partner for safety assessment services. The incremental work will transition to us over the next 12 to 18 months and meaningfully expand our relationship with this find.

Passages & reports (2)
  • The execution of these kinds of initiatives is already benefiting us with clients because …
  • top 10 biopharmaceutical company to serve as a primary strategic partner for safety assess…

With regard to overall demand trends, we are pleased that the improving biopharmaceutical demand environment has remained consistent in recent months and continues to show positive momentum. We are monitoring developments related to inflation, oil prices, interest rates, and the general macroeconomic environment, as well as biotech funding trends for any signs of disruption, but to date, we continue to expect the demand environment to trend favorably.

This view is further supported by our internal demand KPIs, which
I will discuss in more detail shortly. Our revenue from both global biopharmaceutical and small and mid sized biotechnology clients increased on an organic basis in the third quarter. There are several factors contributing to these positive trends. First, many of our large biopharmaceutical clients have progressed through their restructuring activities and are in reinvesting in their RD pipelines, including their preclinical or I and D enabling programs, which is a positive indicator for future demand.

In
addition, as has been well chronicled, ?the biotech funding environment has improved meaningfully since the middle of last year, with trailing twelve month funding remaining just below $100 billion despite a modest slowdown in the third quarter. We are not seeing any signs of slowdown in our client interest, supported by another strong increase in DSA proposal activity in the third quarter. This is an indicator that supports our belief that favorable domain trends will continue.

Passages & reports (8)
  • With regard to overall demand trends, we are pleased that the improving biopharmaceutical …
  • the general macroeconomic environment, as well as biotech funding trends for any signs of …
  • I will discuss in more detail shortly. Our revenue from both global biopharmaceutical and …
  • trends. First, many of our large biopharmaceutical clients have progressed through their r…
  • addition, as has been well chronicled,
  • the
  • biotech funding environment has improved meaningfully since the middle of last year, with …
  • supported by another strong increase in DSA proposal activity in the third quarter. This i…

And finally, the DSA bookings improvement over the past four quarters, during which time our net book to bill has averaged approximately one point one times, has begun to work through the backlog, and we're beginning to see the benefits as demonstrated by the improvement in the third quarter revenue growth to the mid-single digits organically for the DSA segment and total company. I will now provide some highlights from our financial performance before Glenn provides additional detail.

First, we are pleased that our third quarter results exceeded our
prior outlook for revenue and non-gap earnings per share. Third quarter revenue increased 4.7% to the highest level since the second quarter of 2023, with a solid performance in both the DSA and manufacturing segments.

Passages & reports (3)
  • And finally, the DSA bookings improvement over the past four quarters, during which time o…
  • revenue growth to the mid-single digits organically for the DSA segment and total company.…
  • prior outlook for revenue and non-gap earnings per share. Third quarter revenue increased …

The operating margin increased 330 basis points year by year and 250 basis points sequentially to 23%, due to operating leverage from higher study volume and lower nonhuman primate sourcing costs in the DSA segment and the four quarter impact of the divestitures, particularly in the manufacturing segment. Non GAAP earnings per share of $3.09 increased 27% year by year and also exceeded our prior outlook due to the strong top line performance and a lower tax rate.

Based on our strong third quarter financial performance, we are raising our full year revenue guidance by 100 basis points to organic growth above 1.5%, and non gap earnings per share by 15 cents at midpoint to
$11.35 to $11.55. As we discussed at our Invest Today, we are pleased to see earnings power return as our growth rate accelerates and we generate meaningful operating margin expansion.

The organic
revenue growth rate in each of our business segments also improved from second quarter levels. DSA revenue growth improved to 5.9% organically in the third quarter, primarily driven by robust demand for safety assessment studies utilizing non-human primates as well as growth for bioanalysis services. As we discussed at our Invest Today, we believe that we have competitive advantages in the areas of nonhuman primate supply and preclinical bioanalysis services.

They are expected to be important growth drivers and differentiators for Charts
River in the future, particularly as demand for biologics and other complex therapies continues to intensify. Regarding the DSA pricing environment, we are beginning to modestly reduce the level of discounting in recent proposals. Our goal over time will be to cover annual cost inflation through price increases and receive the value of services that we provide to our clients.

While we are early in this process and are not yet seeing it benefit DSA revenue, we are winning proposals and maintained our capture rate during
the third quarter. Assuming the passive trends hold, we do not expect to see any benefit from pricing until at least the second half of next year, due to the normal lack as newly booked studies work through the backlog.

Passages & reports (9)
  • The operating margin increased 330 basis points year by year and 250 basis points sequenti…
  • quarter impact of the divestitures, particularly in the manufacturing segment. Non GAAP ea…
  • tax rate. Based on our strong third quarter financial performance, we are raising our full…
  • $11.35 to $11.55. As we discussed at our Invest Today, we are pleased to see earnings powe…
  • revenue growth rate in each of our business segments also improved from second quarter lev…
  • for bioanalysis services. As we discussed at our Invest Today, we believe that we have com…
  • River in the future, particularly as demand for biologics and other complex therapies cont…
  • will be to cover annual cost inflation through price increases and receive the value of se…
  • the third quarter. Assuming the passive trends hold, we do not expect to see any benefit f…

As I've already mentioned, from a demand perspective, we were pleased to see continued strengths in the DSA demand KPIs in the third quarter. Net bookings increased 32% year by year to $652 million as we anniversary the softer bookings that occurred through the third quarter of last year. This resulted in a net book to bill of 1.09 times, as well as both year-by-year and sequential increases in the DSA backlog to $2,030,000.

This continues to firmly support our
long-term financial targets, including 5-7% DSA organic revenue growth. As I mentioned, proposals showed a strong increase again, marking the fifth consecutive quarter of year-over-year improvement. These trends collectively support our expectation for continued mid-single-digit DSA organic growth in the fourth quarter of this year. Both global biopharmaceutical and small and mid-sized biotechnology clients continue to be key contributors to the demand improvement.

Manufacturing
revenue rebounded to 7.4% organic growth, with similar growth rates in both the microbial solutions and biologics testing solutions businesses. We were pleased to see the growth rate return to levels that are consistent with our long-term targets for this segment. Our manufacturing quality control testing portfolio leverages many of the strengths of our DSA offering, including enabling clients to drive greater speed and efficiency, and also creates additional growth opportunity by deepening our client relationships across the drug development lifecycle.

Now that we have divested the CDMO business and anniversary the decline specific issue that has been a headwind for the biologics testing business. Since mid 2025, we are more clearly seeing the revenue growth and marginal
potential for the manufacturing segment.

Passages & reports (8)
  • As I've already mentioned, from a demand perspective, we were pleased to see continued str…
  • occurred through the third quarter of last year. This resulted in a net book to bill of 1.…
  • long-term financial targets, including 5-7% DSA organic revenue growth. As I mentioned, pr…
  • support our expectation for continued mid-single-digit DSA organic growth in the fourth qu…
  • revenue rebounded to 7.4% organic growth, with similar growth rates in both the microbial …
  • manufacturing quality control testing portfolio leverages many of the strengths of our DSA…
  • lifecycle. Now that we have divested the CDMO business and anniversary the decline specifi…
  • potential for the manufacturing segment.

Speaker 2

from academic and government accounts was relatively stable globally for the entire RMS segment in the third quarter, as higher revenue in the insourcing solutions business related to government contract awards was offset by lower small model volumes in North America, reflecting continued pressure from uncertainty in government funding. This is one of the reasons that the RMS growth rate has not yet begun to reaccelerate as it has in the DSA and manufacturing segments because global academic and government clients represent a larger portion of RMS revenue at nearly 40%.

Passages & reports (3)
  • from academic and government accounts was relatively stable globally for the entire RMS se…
  • pressure from uncertainty in government funding. This is one of the reasons that the RMS g…
  • revenue at nearly 40%.

AI has gotten a lot of attention in recent weeks, so in closing, I want to reaffirm our views on the potential benefits of AI. First, as I noted at our Investor Day, we believe AI will be a tailwind to our business in the coming years and increase the number of programs that progress through the regulated drug development process, including safety assessment. However, gauging the potential impact of AI on the RD process will take time because the measure of success will be when more drugs discovered using AI progress through the I and D enabling process and into the clinic.

But as I said, we are well positioned to take part in this process, as demonstrated by our recent collaboration with Eli Lilly's Toon Lab initiative and the scientific breadth and depth of our portfolio.

Passages & reports (3)
  • AI has gotten a lot of attention in recent weeks, so in closing, I want to reaffirm our vi…
  • that progress through the regulated drug development process, including safety assessment.…
  • D enabling process and into the clinic. But as I said, we are well positioned to take part…

Beyond the potential benefits of AI, we are encouraged by the continued strengths of the underlying biopharmaceutical demand environment. While there are still pockets that have not yet begun to improve, from DSA pricing and startup biotech activity to academic and government client demand, we are pleased with the progress that we have made and the gross prospects ahead. We also see significant opportunities to further strengthen Chantriva's competitive position.

With our financial strengths, focused strategy, and deep expertise in regulated testing across the
drug development continuum, we are well positioned to meet growing client demand for scientific innovation, speed and efficiency. Through Pathway to Purpose, we are building a more agile, client centric organization that will deepen client relationships, expand engagement across our portfolio, and increase our share of R D spend as demand trends continue to improve.

Now I will turn the call over to Glenn Coleman to provide more details on our third quarter financial performance as well as to
update our 2026 guidance.

Passages & reports (5)
  • Beyond the potential benefits of AI, we are encouraged by the continued strengths of the u…
  • pleased with the progress that we have made and the gross prospects ahead. We also see sig…
  • drug development continuum, we are well positioned to meet growing client demand for scien…
  • relationships, expand engagement across our portfolio, and increase our share of R D spend…
  • update our 2026 guidance.

Speaker unclear

?Thank you,

Passages & reports (1)
  • Thank you,

Speaker 1

Beergate, and good morning. As a reminder, my comments on financial performance will largely be related to non GAAP results, which exclude amortization and other acquisition and divestiture related adjustments, costs related primarily to restructuring and efficiency initiatives, and certain other items. Many of my comments will also refer to organic revenue growth, which excludes the impact of acquisitions to vestitures and foreign currency translation.

We were pleased with our solid third quarter financial results, as both revenue and non gap earnings per share exceeded our prior outlook. Organic revenue increased 4.7%
year over year, marking our strongest growth in three years. ?This exceeded our prior outlook of 1 to 3% organic growth, with strength across our portfolio, particularly in the DSA segment.

Passages & reports (5)
  • Beergate, and good morning. As a reminder, my comments on financial performance will large…
  • will also refer to organic revenue growth, which excludes the impact of acquisitions to ve…
  • year over year, marking our strongest growth in three years.
  • This
  • exceeded our prior outlook of 1 to 3% organic growth, with strength across our portfolio, …

Speaker unclear

?The

Passages & reports (1)
  • The

Speaker 1

non-GAP operating margin improved 250 basis points sequentially to 23%, driven by the DSA and manufacturing segments, as well as lower corporate costs. Non-GAP earnings per share of $3.09 increased 27.2% year over year, which was above our prior outlook of $2.90 to $3, as a result of the stronger than expected operating income driven by higher revenue as well as a lower tax rate.

Moving to segment details, DSA revenue was $596 million in the third quarter, an increase of
5.9% on an organic basis, driven by higher volume for regulated safety assessment services, including the continued strong demand ?for non-human primate related studies and bioanalysis services. This is the second consecutive quarter of revenue growth in the DSA segment as we continue to see the benefits of the improved biopharmaceutical demand trends, which began at the end of last year.

Passages & reports (5)
  • non-GAP operating margin improved 250 basis points sequentially to 23%, driven by the DSA …
  • outlook of $2.90 to $3, as a result of the stronger than expected operating income driven …
  • 5.9% on an organic basis, driven by higher volume for regulated safety assessment services…
  • for
  • non-human primate related studies and bioanalysis services. This is the second consecutive…

Speaker unclear

?As

Passages & reports (1)
  • As

Speaker 1

Birgit mentioned, we continued to see strong demand, including the third quarter net book to bill of 1.09 times and strong proposal growth. Year over year, the DSA operating margin increased by 140 basis points to 26.8%, primarily due to improved operating leverage as a result of the higher study volume ?and the benefit of lower sourcing costs for Cambodia non-human primates. Looking ahead, ?we expect the DSA operating margin to continue to improve sequentially in the fourth quarter as we expect to realize further benefits from Cambodia NHP sourcing and also lower fringe benefit costs, which are typically more favorable later in the

Passages & reports (6)
  • Birgit mentioned, we continued to see strong demand, including the third quarter net book …
  • operating leverage as a result of the higher study volume
  • and
  • the benefit of lower sourcing costs for Cambodia non-human primates. Looking ahead,
  • we
  • expect the DSA operating margin to continue to improve sequentially in the fourth quarter …

Speaker unclear

?year.

Passages & reports (1)
  • year.

Speaker 1

Shifting to the manufacturing segment, third quarter revenue of $179 million increased 7.4% on an organic basis. The strong performance was driven by both the microbial solutions and biologics testing businesses. Microbial Solutions delivered organic revenue growth similar to the segment average, reflecting continued strong demand across our three major geographic regions for endotoxin testing reagents, including our PTS rapid testing cartridges.

Passages & reports (2)
  • Shifting to the manufacturing segment, third quarter revenue of $179 million increased 7.4…
  • to the segment average, reflecting continued strong demand across our three major geograph…

Speaker unclear

?In

Passages & reports (1)
  • In

Speaker 1

addition, we were pleased by the placement of nine automated endosafe Nexus instruments in the third quarter, which we expect will drive meaningful incremental cartridge use over ?time. Our Celsius BioBurden testing platform also reported solid revenue growth from both reagents and instrument placements, which supports pharmaceutical clients' broader microbial testing needs. The placement of the new systems demonstrates the value of our comprehensive rapid testing solutions and helping clients improve the speed and efficiency of manufacturing quality control and product release testing. ?

The
biologics testing business also grew at a high single-digit organic rate, primarily driven by strong demand for in vitro biosafety and analytical testing. We also anniversaried a client-specific challenge that had been a headwind since the middle of last ?year. The manufacturing operating margin improved to 38.6%, representing improvement of 80 basis points sequentially and nearly twelve hundred basis points year over year, driven primarily by the full quarter benefit of the C DMO divestiger, as well as operating leverage from the strong top line performance.

We continue to expect manufacturing will be an important contributor to overall operating margin improvement, with continued progress expected in the fourth quarter approaching forty percent. Wrapping up the segment discussion, RMS reported revenue of $208 million in the quarter, representing an organic decline
of 0.6% year over ?year. The decline was largely driven by lower revenue for small research models in North America, as well as lower revenue for nonhuman primat sold to third parties due primarily to the timing of shipments. ?

We
also plan to use more nonhuman primates on internal DSA studies going forward.

Passages & reports (14)
  • addition, we were pleased by the placement of nine automated endosafe Nexus instruments in…
  • time. Our
  • Celsius BioBurden testing platform also reported solid revenue growth from both reagents a…
  • efficiency of manufacturing quality control and product release testing.
  • The
  • biologics testing business also grew at a high single-digit organic rate, primarily driven…
  • year. The
  • manufacturing operating margin improved to 38.6%, representing improvement of 80 basis poi…
  • We continue to expect manufacturing will be an important contributor to overall operating …
  • of 0.6% year over
  • year. The
  • decline was largely driven by lower revenue for small research models in North America, as…
  • We
  • also plan to use more nonhuman primates on internal DSA studies going forward.

Speaker unclear

?The

Passages & reports (1)
  • The

Speaker 1

decline was largely offset by strong demand for small models in China, which grew at a double-digit rate as there continues to be significant investment in RD in China. ?The RMS segment also benefited from higher revenue for research model services driven by the in-sourcing solutions business, which has benefited this year from new government contract awards. Cradle operations have been stable but have not returned to growth as the early stage biotech environment, including new biotech company starts, has yet to meaningfully improve.

RMS operating margin declined by 60 basis points year over year to 24.4%,

Passages & reports (4)
  • decline was largely offset by strong demand for small models in China, which grew at a dou…
  • The
  • RMS segment also benefited from higher revenue for research model services driven by the i…
  • company starts, has yet to meaningfully improve. RMS operating margin declined by 60 basis…

Speaker unclear

?due

Passages & reports (1)
  • due

Speaker 1

largely to unfavorable revenue mix, both geographically as we continue to experience higher growth in China than in North America, and also the lower non-human primate revenue. We expect the RMS margin to be modestly lower sequentially in the fourth quarter, due primarily to normal seasonality in the business. Moving on to other financial metrics, for the third quarter, unallocated corporate costs totaled $54 million or 5.5% of revenue compared to 5.9% in the prior year period.

As we anticipated, the decrease was primarily driven by lower
fringe-related costs, including stock compensation and deferred compensation expense. We continue to expect unallocated corporate costs of approximately 6% percent of revenue for the full year. Net interest expense was twenty six million dollars in the third quarter, an increase of two point five million dollars year over year. ?At the end of the third quarter, gross and net leverage improved sequentially to two point three times, due primarily to lower debt levels and improved earnings.

This improvement reflected our continued focus on disciplined capital allocation, including the balanced use of cash to fund strategic acquisitions earlier
this year and our ability to quickly repay debt. ?For the full year, our net interest expense outlook is expected to be at the upper end of our previous guidance range of $103 to $108 million on a non-GAP basis, due in part to higher interest rates.

Passages & reports (9)
  • largely to unfavorable revenue mix, both geographically as we continue to experience highe…
  • business. Moving on to other financial metrics, for the third quarter, unallocated corpora…
  • fringe-related costs, including stock compensation and deferred compensation expense. We c…
  • point five million dollars year over year.
  • At
  • the end of the third quarter, gross and net leverage improved sequentially to two point th…
  • this year and our ability to quickly repay debt.
  • For
  • the full year, our net interest expense outlook is expected to be at the upper end of our …

Speaker unclear

?The

Passages & reports (1)
  • The

Speaker 1

third quarter non-GAP tax rate was 22.8%, a decrease of 550 basis points year over year. ?The higher tax rate in the prior year period resulted from the enactment of the One Big Beautiful Bill, or OB three, ?and the enactment of certain global minimum tax provisions. ?For the full year, we expect a non gap tax rate of approximately twenty three percent, which is at the lower end of our prior guidance range, as the impact of the tax legislation changes in the foreign jurisdiction that I discussed during the second quarter earnings call were more favorable than anticipated.

Passages & reports (7)
  • third quarter non-GAP tax rate was 22.8%, a decrease of 550 basis points year over year.
  • The
  • higher tax rate in the prior year period resulted from the enactment of the One Big Beauti…
  • and
  • the enactment of certain global minimum tax provisions.
  • For
  • the full year, we expect a non gap tax rate of approximately twenty three percent, which i…

Free cash flow was $207 million in the third quarter, an increase of $29 million compared to the prior year period. This increase was largely driven by the timing of working capital. CAPEX increased to $47 million or approximately 4.8% of revenue in the third quarter from $36 million last year as we continue to invest in growth and margin expansion initiatives. ?For 2026, we continue to expect CapEx will be approximately $200 million, unchanged from our prior outlook and in line with our long-term targeted level of 5-6% of revenue.

Our free cash flow outlook also remains unchanged at $400 to $420 million.

Passages & reports (4)
  • Free cash flow was $207 million in the third quarter, an increase of $29 million compared …
  • million last year as we continue to invest in growth and margin expansion initiatives.
  • For
  • 2026, we continue to expect CapEx will be approximately $200 million, unchanged from our p…

Turning to full year 2026 PL guidance, we are increasing both the reported and organic revenue outlook due to better than expected top line performance across all three segments in the third quarter, particularly the DSA segment. We now expect a reported revenue decline of 1.5% to 2%, with year-over-year decline driven by the impact of completed devestitures. We're also raising our organic revenue growth guidance for the year to be at least 1.5% growth, which represents a 100 basis point improvement compared to our prior guidance. ?

We
are narrowing and modestly increasing our organic revenue growth outlook for each segment, and now expect DSA to be above 2% growth, manufacturing at a mid-single digit growth rate, and RMS at a low single-digit organic decline. Moving to profitability, we continue to expect operating margin expansion of approximately 120 to 150 basis points in 2026, with the manufacturing and DSA segments driving the year-over-year increase.

Passages & reports (5)
  • Turning to full year 2026 PL guidance, we are increasing both the reported and organic rev…
  • 2%, with year-over-year decline driven by the impact of completed devestitures. We're also…
  • We
  • are narrowing and modestly increasing our organic revenue growth outlook for each segment,…
  • we continue to expect operating margin expansion of approximately 120 to 150 basis points …

Speaker unclear

?We

Passages & reports (1)
  • We

Speaker 1

are increasing our non-gap earnings per share guidance by 15 cents at the midpoint to a range of eleven dollars and thirty-five cents to eleven dollars and fifty-five cents, which represents ten to twelve percent year-over-year growth. ?The increase reflects the top-line outperformance in the third quarter, dropping through to earnings as well as a lower than expected tax

Passages & reports (3)
  • are increasing our non-gap earnings per share guidance by 15 cents at the midpoint to a ra…
  • The
  • increase reflects the top-line outperformance in the third quarter, dropping through to ea…

Speaker unclear

?rate.

Passages & reports (1)
  • rate.

Speaker 1

With one quarter remaining, our fourth quarter outlook is effectively embedded in our full year guidance. Looking at the revenue trends, we expect the DSA and manufacturing segments organic growth will remain at mid-single digit and high single digit rates respectively in the fourth quarter, while we have forecast a modest reduction in the RMS growth ?rate. We expect continued sequential operating margin improvement of approximately 150 basis points due largely to the benefit of lower sourcing costs for Cambodia non-human primates in the DSA segment, favorable related costs, ?and higher sales volume related to normal year-end order patterns in microbial solutions.

This is expected to result in non-gap earnings per share growth of approximately 30 to 40% year over year. Before I conclude, I'd like to address how we are positioning our financial performance for next
?year. We expect to provide our 2027 financial guidance with our fourth quarter earnings in February. Our view towards 2027 is the same as I discussed at our investor day in September.

At this time, we expect a gradual improvement in 2027 from the organic growth rate in 2026,
?and assuming the favorable market trends continue, revenue growth increasing to the targeted 5 to 7% range starting in 2028.

Passages & reports (10)
  • With one quarter remaining, our fourth quarter outlook is effectively embedded in our full…
  • growth
  • rate.
  • We expect continued sequential operating margin improvement of approximately 150 basis poi…
  • and
  • higher sales volume related to normal year-end order patterns in microbial solutions. This…
  • year.
  • We expect to provide our 2027 financial guidance with our fourth quarter earnings in Febru…
  • and
  • assuming the favorable market trends continue, revenue growth increasing to the targeted 5…

Speaker unclear

?In

Passages & reports (1)
  • In

Speaker 1

2027, we expect operating margin improvement will be higher than the 75 basis point average through 2030 that we discussed at the investor day, largely due to a full year benefit of acquisitions and divestitures completed in 2026, as well as top line leverage and our Create the Future Cost Savings initiatives. To conclude, the third quarter financial results demonstrate the strength of our streamlined portfolio and our continued focus on operational execution. ?

We
are encouraged by the improving end market demand trends and our execution against key strategic initiatives, both of which we expect will support gradual progress towards our long term financial targets. Our pathway to purpose priorities will modernize how we work, strengthen our scientific leadership and portfolio, and enhance our client-centric approach as we continue to position Charles River to deliver profitable growth and long term shareholder value.

Thank

Passages & reports (5)
  • 2027, we expect operating margin improvement will be higher than the 75 basis point averag…
  • initiatives. To conclude, the third quarter financial results demonstrate the strength of …
  • We
  • are encouraged by the improving end market demand trends and our execution against key str…
  • and enhance our client-centric approach as we continue to position Charles River to delive…

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 3

Unverified voice label

Thanks, Glenn. That concludes our comments, and we will now take your questions.

Passages & reports (1)
  • Thanks, Glenn. That concludes our comments, and we will now take your questions.

Speaker unclear

?Thank

Passages & reports (1)
  • Thank

Speaker 0

you very much, Mr. Spencer. Ladies and gentlemen, that's the time. If you do have any questions, please press star one. If you would like to remove yourself from the queue, you can do so by pressing star two. Once again, star one for questions, and we ask that you please limit yourself to one question and one follow up. We'll go first this morning to Elizabeth Anderson with Evercore ISI.

Passages & reports (2)
  • you very much, Mr. Spencer. Ladies and gentlemen, that's the time. If you do have any ques…
  • question and one follow up. We'll go first this morning to Elizabeth Anderson with Evercor…

Speaker 4

Unverified voice label

Hi guys, good morning. Thanks so much for the question. Um I I appreciate the comment um on the demand environment. Obviously you have a lot of different business lines and lots of different things are happening. If you talking about you talked about for 2027 that gradual improvement towards the five to seven percent in 2028. Can you just talk to us a little bit more maybe sort of operationally sort of like what improves faster, what is improving maybe towards the later part of that.

You know, maybe even if it's qualitative commentary, I think that would just help us to understand um the the pace of improvement
and and sort of what you're seeing in the market from there. Thank

Passages & reports (3)
  • Hi guys, good morning. Thanks so much for the question. Um I I appreciate the comment um o…
  • in 2028. Can you just talk to us a little bit more maybe sort of operationally sort of lik…
  • and and sort of what you're seeing in the market from there. Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 2

Yeah, certainly. Thanks,

Passages & reports (1)
  • Yeah, certainly. Thanks,

Speaker 5

Unverified voice label

Elizabeth. Happy to. So yes, um so what we're looking at um right now is is what we're actually seeing, right? So we're looking at our proposals overall, uh they have been increasing. Net book to bill um continues to be strong

Passages & reports (1)
  • Elizabeth. Happy to. So yes, um so what we're looking at um right now is is what we're act…

Speaker 2

for the

Passages & reports (1)
  • for the

Speaker 5

trending 12

Passages & reports (1)
  • trending 12

Speaker 2

months

Passages & reports (1)
  • months

Speaker 5

1.1 um as an

Passages & reports (1)
  • 1.1 um as an

Speaker 2

average so definitely helping our um or supporting the long range uh target that we have. And what we are also seeing is a return to revenue growth. Now for the second quarter of the the Q two was was kind of moderate, but the third quarter revenue growth is is right where we expected it, a little bit better actually. And so what we are looking for and and what we are currently seeing in all our forward looking metrics is including proposals, gross bookings, net bookings, even capture rates, is a gradual return to growth, building on the pretty good revenue growth rate that we have been seeing in Q3 going into next year.

What we uh most of that or just about all of that right now is volume driven.

Passages & reports (3)
  • average so definitely helping our um or supporting the long range uh target that we have. …
  • growth is is right where we expected it, a little bit better actually. And so what we are …
  • rates, is a gradual return to growth, building on the pretty good revenue growth rate that…

And what we have not yet seen really is a return to pricing power, particularly not in the DSA segment. As we said in our prepared remarks, uh we are gradually um reducing the discounting, uh we are uh maintaining uh proposal growth, we are maintaining our capture rates. So all looking really good, uh but even from a timing perspective, if this holds um and accelerates, we won't see uh much of an impact before the second half of next year.

And um otherwise we are seeing good
growth rates now back in our manufacturing segment, right where we expect it to see for our long-range financial targets. DSA is coming along with the exception, as I said, of pricing. And then for research models and services, we still have some headwinds that we need to work through. A lot of that comes from academic and government, offset by strong growth in China, and we expect that to take a little while before it works itself out.

So really uh everything we're seeing is positively uh improving, um setting us up for a gradual
improvement, uh working through itself by uh the second half of next year, and then um with a little bit more pricing power, we think we're um right there where we want it to be or what we said at the investor day, getting to our long range financial target.

Did that answer your question,
Elizabeth?

Passages & reports (6)
  • And what we have not yet seen really is a return to pricing power, particularly not in the…
  • our capture rates. So all looking really good, uh but even from a timing perspective, if t…
  • growth rates now back in our manufacturing segment, right where we expect it to see for ou…
  • that comes from academic and government, offset by strong growth in China, and we expect t…
  • improvement, uh working through itself by uh the second half of next year, and then um wit…
  • Elizabeth?

Speaker 4

Yeah, that was that was super helpful. Thank you very much. And I know, you know, probably, you know, you just sort of updated us on the call on a couple weeks ago regarding AI. But you know, as we start to see those molecules, you know, we've heard seen reports in in of you know molecules in discovery being used by AI. Is that what kind of trajectory in general does that take to sort of get molecules from that discovery phase into safety and sort of start to see that?

Is that kind of twenty eight? Is that longer sort of like I I and obviously I know
the answer depends but just sort of directionally speaking how does that how does that work? I'm sorry if that's a bit of an unfair question.

Passages & reports (3)
  • Yeah, that was that was super helpful. Thank you very much. And I know, you know, probably…
  • know molecules in discovery being used by AI. Is that what kind of trajectory in general d…
  • the answer depends but just sort of directionally speaking how does that how does that wor…

Speaker 2

No, no, no, not at all. So

Passages & reports (1)
  • No, no, no, not at all. So

Speaker 5

I mean um the

Passages & reports (1)
  • I mean um the

Speaker 2

the the work ?with AI didn't start this year. It started literally a decade ago and so what we are seeing right now is obviously an acceleration. Uh we do uh work with a quite a few of the AI discovery companies and um so they are they have um programs in the preclinical phase, some even in the clinical phase. But what we are expecting to see is just an uh an improving rate or more of those companies, more programs coming into the validation space or the validation process that we are doing for those companies.

So we're seeing some now.

Passages & reports (4)
  • the the work
  • with
  • AI didn't start this year. It started literally a decade ago and so what we are seeing rig…
  • phase, some even in the clinical phase. But what we are expecting to see is just an uh an …

We'll see an improving amount of those companies. And then frankly, I I I I would say in two years it's going to be hard to tell who is AI native and who uses AI and who doesn't use AI. I think just about everybody will turn into a nearly AI native company. And the positive thing about all of that is it's bringing a lot of interest into the space, into the healthcare space, biotech companies seeing more funding, um, partially or maybe to a good amount because of AI.

And so eventually this will just all kind of mix itself uh
into just an accelerated amount of uh I and D enabling programs, um strengthening our pipeline, um, ending up in our backlog. So all positive.

Passages & reports (3)
  • We'll see an improving amount of those companies. And then frankly, I I I I would say in t…
  • And the positive thing about all of that is it's bringing a lot of interest into the space…
  • into just an accelerated amount of uh I and D enabling programs, um strengthening our pipe…

Speaker 4

Very helpful. Thank you so

Passages & reports (1)
  • Very helpful. Thank you so

Speaker unclear

?much.

Passages & reports (1)
  • much.

Speaker 2

Thanks, Elizabeth.

Passages & reports (1)
  • Thanks, Elizabeth.

Speaker unclear

?Thank

Passages & reports (1)
  • Thank

Speaker 0

you. We'll go next now to Ryan Halstedt with R B C.

Passages & reports (1)
  • you. We'll go next now to Ryan Halstedt with R B C.

Speaker unclear

?Morning. Thanks for taking the question. Maybe just sticking with the AI.

Passages & reports (1)
  • Morning. Thanks for taking the question. Maybe just sticking with the AI.

Speaker 6

Unverified voice label

Um ?you know a lot of investor focus on the topic, so uh I appreciate uh asking the the question um is around your bookings and and the strong book to bill. I mean, is there a way to gauge just how much of your bookings and book to bill is just, you know, the improving sort of biotech uh environment and R and D spend and and how much is really coming from AI already?

Um that's kind of my first question.

Passages & reports (4)
  • Um
  • you
  • know a lot of investor focus on the topic, so uh I appreciate uh asking the the question u…
  • sort of biotech uh environment and R and D spend and and how much is really coming from AI…

Speaker 5

Yeah, uh Ryan, it's a really, really good question. And one we we literally just talked about. So it's it's really hard because as I said, there are typical AI companies that you would definitely all of us would say they are A

Passages & reports (1)
  • Yeah, uh Ryan, it's a really, really good question. And one we we literally just talked ab…

Speaker 2

AI native, and then there are um most discovery companies I would say using our AI in some form or fashion. So it's it would be extremely manual and not a um an accurate science to really try to say what comes from AI companies and what doesn't. Um yesterday there was actually a report that ?was quite helpful and uh I thought well done um that kind of split out the AI discovery funding from uh the normal biotech funding.

And that's probably the best number I we could would give you, um, which was for the last quarter over nine hundred million. But in our
order book it's really difficult because um everybody's now using AI and it doesn't really make a lot of sense to really split out uh AI versus non AI. It what I'm looking for is AI is driving interest in the sector.

It's driving interest in uh investments
and that will benefit all of

Passages & reports (6)
  • AI native, and then there are um most discovery companies I would say using our AI in some…
  • and what doesn't. Um yesterday there was actually a report that
  • was
  • quite helpful and uh I thought well done um that kind of split out the AI discovery fundin…
  • order book it's really difficult because um everybody's now using AI and it doesn't really…
  • and that will benefit all of

Speaker unclear

?us.

Passages & reports (1)
  • us.

Speaker 6

Very helpful. I appreciate that. And then maybe my follow up, just switching gears to to Nan's. ?You know, you talked about uh the virtual control groups moving from concept to practice. I guess just any more uh thoughts on you know how how meaningful do you expect to be incorporating uh virtual control groups into your your work across all of your customers?

Passages & reports (3)
  • Very helpful. I appreciate that. And then maybe my follow up, just switching gears to to N…
  • You
  • know, you talked about uh the virtual control groups moving from concept to practice. I gu…

Speaker 5

Yeah, um happy to. So um names

Passages & reports (1)
  • Yeah, um happy to. So um names

Speaker 2

is the the right ethical and scientific direction. So um obviously we are very committed to reducing the number of animals in studies. Therefore, Virtual Control Group is an incredible important and rewarding program that we have, and to see it now coming out of basically validation and proof of concept into actually using it on a real study and providing that data to the FDA is really great to see.

So it's a big, big milestone. From a scientific perspective, we
are looking to provide our clients with better answers, better insights, better data. Virtual control groups can provide that in certain instances. So another important point from a revenue perspective, we are looking to s for uh getting paid for our investment. I wouldn't look at it as a huge revenue upside. I would say it's it's probably right alongside uh the um being paid for regular control groups.

So um it does kind of even out, but scientifically and from an uh a a direction of
reducing the number of animals, that's it's a great milestone.

Passages & reports (5)
  • is the the right ethical and scientific direction. So um obviously we are very committed t…
  • now coming out of basically validation and proof of concept into actually using it on a re…
  • are looking to provide our clients with better answers, better insights, better data. Virt…
  • for our investment. I wouldn't look at it as a huge revenue upside. I would say it's it's …
  • reducing the number of animals, that's it's a great milestone.

Speaker 6

Very helpful. Thank

Passages & reports (1)
  • Very helpful. Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker unclear

?Thank

Passages & reports (1)
  • Thank

Speaker 0

you. We go next now to Luke Sergat with Barclays.

Passages & reports (1)
  • you. We go next now to Luke Sergat with Barclays.

Speaker unclear

?Hey, great. Um just wanted to talk a little bit continue on the AI trend and and

Passages & reports (1)
  • Hey, great. Um just wanted to talk a little bit continue on the AI trend and and

Speaker 7

Unverified voice label

uh demand that you guys are seeing and you know, I understand that that everybody's gonna be using it, but can you give us a sense of you know the difference in dollar per program or dollar per molecule? Any changes from you know amount of services being used or anything like that from like one of these native AI biotech customers versus kind of what you saw legacy?

Because there's a argument against it is that it's just going to reduce overall volumes. Longer term it will, I think everybody understands that
?you know increased efficiency, et cetera, you'll see overall volumes in the long term, but there's uh a small bear contingent talking about near-term disruption to to lower to overall lower dollar value.

Passages & reports (4)
  • uh demand that you guys are seeing and you know, I understand that that everybody's gonna …
  • like that from like one of these native AI biotech customers versus kind of what you saw l…
  • you know
  • increased efficiency, et cetera, you'll see overall volumes in the long term, but there's …

Speaker 2

Yeah, um happy to. Um so Luke, uh the way we are seeing that, so

Passages & reports (1)
  • Yeah, um happy to. Um so Luke, uh the way we are seeing that, so

Speaker 5

the the uh AI discovered molecules, um that is

Passages & reports (1)
  • the the uh AI discovered molecules, um that is

Speaker 2

really, really early stage. So target identification, designing better molecules. That may disrupt a little bit the chemistry space. And that's an area that we divested earlier this year. So we don't expect any any impact on our revenues. And then all of those molecules, they are now much easier to develop. The molecules are easier to spin out. That's why everybody says, okay, that's cheaper, that's more efficient, more productive.

That will translate into more programs. All of those programs still need to be validated and safety tested. And that's
that's the area that we're strong in, we're focusing on. That's the work we do. So from a dollar amount of per program, there

Passages & reports (3)
  • really, really early stage. So target identification, designing better molecules. That may…
  • of those molecules, they are now much easier to develop. The molecules are easier to spin …
  • that's the area that we're strong in, we're focusing on. That's the work we do. So from a …

Speaker unclear

?is no difference for us.

Passages & reports (1)
  • is no difference for us.

Speaker 2

So it doesn't matter if it's AI designed, doesn't matter if it is from an AI native company or non-AI native company, they come in with the same regulatory process requirement than any other program would have. In terms of more programs or less programs, qualitatively what we're seeing is that often companies with AI platforms that they want to validate they come in with more programs than a generally a biotech company that is a non AI company.

And the reason is a couple of different things. Number one, they have an AI platform that they now need to validate. And the only way to validate it is with shots on goal. So more programs. So if you have only one program it fails, your AI platform fails. If
you have twenty programs, fifteen of those succeed, you have a big strong selling point.

So they just need to have more volume going through that validation space to one teach the platform, but then also to validate the platform. Biotech companies that are
non-AI native generally come in with one program, maybe a backup program, but a lot fewer programs. So that's more qualitatively because, as I said, the boundaries are changing quite a ?bit because everybody starts using AI.

The other thing is that we're seeing, and I think that some of the data out there is confirming that. If you have AI in your name or in your uh description

Passages & reports (7)
  • So it doesn't matter if it's AI designed, doesn't matter if it is from an AI native compan…
  • programs or less programs, qualitatively what we're seeing is that often companies with AI…
  • a non AI company. And the reason is a couple of different things. Number one, they have an…
  • you have twenty programs, fifteen of those succeed, you have a big strong selling point. S…
  • non-AI native generally come in with one program, maybe a backup program, but a lot fewer …
  • bit
  • because everybody starts using AI. The other thing is that we're seeing, and I think that …

Speaker 5

of the company, uh funding seems to be a little bit easier to get. Um so AI native companies

Passages & reports (1)
  • of the company, uh funding seems to be a little bit easier to get. Um so AI native compani…

Speaker 2

have a lot of cash, a

Passages & reports (1)
  • have a lot of cash, a

Speaker 5

lot of funds,

Passages & reports (1)
  • lot of funds,

Speaker 2

and with that they uh can actually run a lot more programs, and uh with that doubling their their potential for success of that AI platform. So again, there it's more qualitatively than quantitatively, but um we do see on a smaller scale kind of those effects.

Passages & reports (2)
  • and with that they uh can actually run a lot more programs, and uh with that doubling thei…
  • effects.

Speaker unclear

?Great.

Passages & reports (1)
  • Great.

Speaker 1

That's that's helpful.

Passages & reports (1)
  • That's that's helpful.

Speaker 7

And then I guess on the um changing gears, I want to talk a bit a little bit about ?the NHP um supply and demand and how that's shaking out. We're getting you know channel checks here that that supply is getting super tight again. Um people locking up multi-years out from when projects gonna start. So talk about what you're seeing there and just update us ?on the exposure across um RMS and and DSA there as we think about, you know, probably back half 27 and 28 when the when the pricing dynamics start to play

Passages & reports (5)
  • And then I guess on the um changing gears, I want to talk a bit a little bit about
  • the
  • NHP um supply and demand and how that's shaking out. We're getting you know channel checks…
  • on
  • the exposure across um RMS and and DSA there as we think about, you know, probably back ha…

Speaker unclear

?out.

Passages & reports (1)
  • out.

Speaker 2

Yeah, um certainly. Um so just to to level set everybody again. So we we use non-human primates in our um safety assessment studies for our clients, and that is the the the primary reason uh we have uh backwards integrated into our supply chain. We now own farms and uh we're happy to say that about um roughly 80% of our estimated usage is um covered by our own supply from our own farms.

And that gives us uh that's a big differentiator and is a big competitive advantage in our
opinion. Um now you're you're asking about um tighter supply. There is definitely a lot of discussion in China about very tight supply of non human primates in in China

Passages & reports (3)
  • Yeah, um certainly. Um so just to to level set everybody again. So we we use non-human pri…
  • own farms and uh we're happy to say that about um roughly 80% of our estimated usage is um…
  • opinion. Um now you're you're asking about um tighter supply. There is definitely a lot of…

Speaker 5

and um we have a farm in China and

Passages & reports (1)
  • and um we have a farm in China and

Speaker 2

w

Passages & reports (1)
  • w

Speaker 5

because

Passages & reports (1)
  • because

Speaker 2

we can't export the animals for our own safety assessment studies, we're actually selling them um through our research models and services business in China. That's a relatively small amount,

Passages & reports (1)
  • we can't export the animals for our own safety assessment studies, we're actually selling …

Speaker 5

relatively small uh revenue base, but uh we are hearing a lot and seeing a

Passages & reports (1)
  • relatively small uh revenue base, but uh we are hearing a lot and seeing a

Speaker 2

lot that there is

Passages & reports (1)
  • lot that there is

Speaker 5

definitely uh

Passages & reports (1)
  • definitely uh

Speaker 2

a need for more ?non human primates in in China and that there is a lot of interest in in that space. Um as I said, not necessarily very material for us, um, but we're watching that market to see where the need goes and then certainly also where pricing goes. This year pricing improved in China uh moderately to levels that we have seen before in recent years, ?and we're going to see what happens in 2027.

Otherwise, we continue to really focus on operational improvement, better control of our supply chain, making sure logistics is in place, and just providing our
clients with that differentiator of having non human climate supply for their studies at the best quality and the best health status possible. And again, as I said, we see that as a differentiator. And just want to point out that when ?we basically sell a safety assessment study, we're selling the whole study.

So the animal is included. So we don't necessarily split out the animal itself. What we have seen this year is an increased need for nonhuman primate
studies studies in the marketplace. And it makes sense because of a lot of complex modalities, a lot of biologics being uh priority for in the pipelines of many of our clients. And we'll have to just see where that continues.

We have um currently enough supply
to meet our long range financial targets and the rest of it we'll just have to see where the marketplace goes, where the science goes and where our clients need go. Did that answer the question?

Passages & reports (11)
  • a need for more
  • non
  • human primates in in China and that there is a lot of interest in in that space. Um as I s…
  • levels that we have seen before in recent years,
  • and
  • we're going to see what happens in 2027. Otherwise, we continue to really focus on operati…
  • clients with that differentiator of having non human climate supply for their studies at t…
  • we
  • basically sell a safety assessment study, we're selling the whole study. So the animal is …
  • studies studies in the marketplace. And it makes sense because of a lot of complex modalit…
  • to meet our long range financial targets and the rest of it we'll just have to see where t…

Speaker 7

Yeah, that's helpful. Thank

Passages & reports (1)
  • Yeah, that's helpful. Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 2

Thanks, Lou.

Passages & reports (1)
  • Thanks, Lou.

Speaker 0

We'll go next now to Justin Bowers with Deutsche Bank.

Passages & reports (1)
  • We'll go next now to Justin Bowers with Deutsche Bank.

Speaker unclear

?Hi,

Passages & reports (1)
  • Hi,

Speaker 6

good morning, Birga. Just piggybacking on that last question, are what are you seeing in terms of therapeutic areas?

Passages & reports (1)
  • good morning, Birga. Just piggybacking on that last question, are what are you seeing in t…

One is just around vaccines and infectious disease. Are you seeing a r um increased interest in investment there? And then part two would be your comment around the partnership with with top ten pharma, just at a

Passages & reports (1)
  • One is just around vaccines and infectious disease. Are you seeing a r um increased intere…

Speaker 3

high level,

Passages & reports (1)
  • high level,

Speaker 6

are you starting to see pharma invest more in in preclinical? And then with acquired biotechs, are they starting to expand uh the number of assets or programs from those acquisitions?

Passages & reports (1)
  • are you starting to see pharma invest more in in preclinical? And then with acquired biote…

Speaker 2

Yeah, so um maybe maybe I'll start with the um the the the well let me start with the therapeutic areas. So what we are definitely seeing is um a high interest and a high amount of programs in the biologic's complex modality space. Um we're seeing um continued interest in vaccines, but I wouldn't say an accelerated interest. So it is more about M RNA, um, you know, maybe ADCs, things like that, um, that um, you know, is is a complex work and actually supports um our competitive differentiation as a specialty provider, um, less so with the vaccine space.

But that hopefully will uh change too, and we might see an uptake there in in the outer years. As far as pharma, so we announced that we have expanded
uh a relationship with one of our um the top ten biopharmaceutical companies. Um that's a um great outcome and a great milestone. We are now really the preferred partner for just about all of the um big clients uh of ours, just showcasing the breadth and depth of our portfolio, our client-centric approach with our clients.

And so we are really, really happy with that. Global biopharmaceutical clients have really really for the last I would say eighteen months um increased the amount of work um
coming out of their restructuring activities. Um bookings are strong, proposals are strong. Um we see quite a bit of growth in that space. So all the indicators, including the revenue that we're seeing, are quite healthy from global biopharmaceutical companies.

So are definitely
uh refocusing on internal development

Passages & reports (7)
  • Yeah, so um maybe maybe I'll start with the um the the the well let me start with the ther…
  • Um we're seeing um continued interest in vaccines, but I wouldn't say an accelerated inter…
  • supports um our competitive differentiation as a specialty provider, um, less so with the …
  • uh a relationship with one of our um the top ten biopharmaceutical companies. Um that's a …
  • showcasing the breadth and depth of our portfolio, our client-centric approach with our cl…
  • coming out of their restructuring activities. Um bookings are strong, proposals are strong…
  • uh refocusing on internal development

Speaker unclear

?um

Passages & reports (1)
  • um

Speaker 5

and

Passages & reports (1)
  • and

Speaker unclear

?um pro getting more

Passages & reports (1)
  • um pro getting more

Speaker 2

drug programs

Passages & reports (1)
  • drug programs

Speaker 5

um

Passages & reports (1)
  • um

Speaker unclear

?into

Passages & reports (1)
  • into

Speaker 2

IND enabling studies and into the clinic. So um just great to see that. And then from a biotech perspective, um our indicators are all healthy too. We've seen really great bookings from them. The pro proposal rates are good, capture rates are good, um and um also seeing a return to revenue growth. Funding overall is good. There's certainly some soft spots that we still would like to fill in, such as early company formation, but I think that will come over time as well.

So overall,
we believe that the demand environment is healthy. It's supporting our outlook for this year and our long range financial target that we have provided. And we're not seeing any disruption either macroeconomically or in our demand KPIs at this point.

Passages & reports (3)
  • IND enabling studies and into the clinic. So um just great to see that. And then from a bi…
  • are good, um and um also seeing a return to revenue growth. Funding overall is good. There…
  • we believe that the demand environment is healthy. It's supporting our outlook for this ye…

Speaker 6

Thank you for the detail I squeezed into, so I'll jump out and queue.

Passages & reports (1)
  • Thank you for the detail I squeezed into, so I'll jump out and queue.

Speaker 2

Thank

Passages & reports (1)
  • Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 0

We'll go next now to Dave Winley of Jeffries.

Passages & reports (1)
  • We'll go next now to Dave Winley of Jeffries.

Speaker 7

Great. Great. Good morning. Thanks for taking my questions. I'm going to move off the primary topic here and ask a question, Birgit, about bioanalytical. ?You have highlighted that an expansion there. In your comments today, uh you you talked about preclinical bio. Some of the areas where I think you're you're expanding are to try to capture or retain business as it moves into clinical.

So I just ask you to you know broaden the the commentary or perspective about
the progress you're seeing in BioA across both preclinical and clinical.

Passages & reports (4)
  • Great. Great. Good morning. Thanks for taking my questions. I'm going to move off the prim…
  • You
  • have highlighted that an expansion there. In your comments today, uh you you talked about …
  • the progress you're seeing in BioA across both preclinical and clinical.

Speaker 5

Yeah,

Passages & reports (1)
  • Yeah,

Speaker 2

um

Passages & reports (1)
  • um

Speaker 5

great catch. Um yeah, Dave, um definitely. So what we said in our uh prepared remarks was that we have a particularly strong differentiation right now in the preclinical space. You're right

Passages & reports (1)
  • great catch. Um yeah, Dave, um definitely. So what we said in our uh prepared remarks was …

Speaker 2

that our interest extends also into the clinical bioanalytical space. And the reason for that is it's the same platforms, it's the same assays, it's the client, the same clientele, and that particular with increasingly complexity of assays and drug programs, we can provide our clients with kind of that consistency across both the preclinical and into the clinical. Um we have the science, we have the partnerships, and I think we can f take some time out of their development

Passages & reports (2)
  • that our interest extends also into the clinical bioanalytical space. And the reason for t…
  • drug programs, we can provide our clients with kind of that consistency across both the pr…

Speaker unclear

?uh

Passages & reports (1)
  • uh

Speaker 5

timeline by

Passages & reports (1)
  • timeline by

Speaker 2

just not having to um change partners midstream when you go from the preclinical into the clinical um process. Um so definitely interested in in both areas. Right now our clinical um um part of our revenues in bioanalysis is uh the minority, but we're looking to grow that over time. So we currently have five organic expansions ongoing in our organization where we're building out existing uh footprint um to uh increase capacity for bioanalytical both for preclinical and clinical.

And we also said in at the Investor Day that we would uh certainly be interested in potential MA when and if we find the right target.

Passages & reports (3)
  • just not having to um change partners midstream when you go from the preclinical into the …
  • the minority, but we're looking to grow that over time. So we currently have five organic …
  • preclinical and clinical. And we also said in at the Investor Day that we would uh certain…

Speaker 7

Great. My follow-up's a little bit of a technical one, but it comes back to the NHP um discussion. I think you're you're describing that you're expecting progressive benefit um from the lower cost NHPs having you know internalized their supply chain um a little bit in three Q, a little more in four Q. I guess I was expecting to see that show up in gross margin and I I do see a little, but maybe not as much as I had expected.

And when we look at how the numbers are falling out from the filing, it looks like DSA SGNA is really low in the quarter. And
and so I wondered if perhaps the geography of where that benefit being acquisition driven is landing, is there something going on there? And relatedly, when you say discount, you're narrowing discounts on bids, that is some amount of price improvement, is it not?

Passages & reports (3)
  • Great. My follow-up's a little bit of a technical one, but it comes back to the NHP um dis…
  • I guess I was expecting to see that show up in gross margin and I I do see a little, but m…
  • and so I wondered if perhaps the geography of where that benefit being acquisition driven …

Just just want to clarify on any speech. Thanks.

Passages & reports (1)
  • Just just want to clarify on any speech. Thanks.

Speaker 2

Yeah, let me take the pricing question and then um I'll let Glenn uh

Passages & reports (1)
  • Yeah, let me take the pricing question and then um I'll let Glenn uh

Speaker 5

go into

Passages & reports (1)
  • go into

Speaker 2

the uh

Passages & reports (1)
  • the uh

Speaker 5

margin

Passages & reports (1)
  • margin

Speaker 2

margin question. So yes, so technically if you narrow the discounts you're getting some pricing power back. And uh we just wanted to point out that we are in the process of doing that. We um are moving from uh strategically using discounts to win work to uh kind of testing the market to make sh to see that we can continue to win work with getting paid for inflation and for the work we do.

But we also wanted to caution that because of this this being in a proposal stage, we'll have need some time to work
it through our backlog into revenues in in the coming year. So that's why I said don't expect anything major till the second half of 2027 before we really see some pricing power here.

Passages & reports (3)
  • margin question. So yes, so technically if you narrow the discounts you're getting some pr…
  • win work to uh kind of testing the market to make sh to see that we can continue to win wo…
  • it through our backlog into revenues in in the coming year. So that's why I said don't exp…

Speaker 7

Got it. Understand

Passages & reports (1)
  • Got it. Understand

Speaker 1

that. On the margin question, I would just say we would expect to see a benefit on gross margin, especially in Q4, with the lower sourcing costs coming from KF Cambodia. ?So that is a big part of the overall operating margin improvement from Q3 to Q4, along with lower fringe costs. And we did see lower fringe costs also in Q3 to help to drive some of the SGNA ?down.

If
you're looking at our uh 10 Q filings, you'll see a pretty significant drop in SGNA. That's associated with a non-gap item with uh a tax release and and reserve reversal that we did, which obviously we don't include as part of our non-gap numbers, but you'll see a big uh adjustment there for that. So you're probably looking at

Passages & reports (6)
  • that. On the margin question, I would just say we would expect to see a benefit on gross m…
  • So
  • that is a big part of the overall operating margin improvement from Q3 to Q4, along with l…
  • down. If
  • you're looking at our uh 10 Q filings, you'll see a pretty significant drop in SGNA. That'…
  • So you're probably looking at

Speaker unclear

?that.

Passages & reports (1)
  • that.

Speaker 7

Yeah, thanks. Thank you. Appreciate the clarification.

Passages & reports (1)
  • Yeah, thanks. Thank you. Appreciate the clarification.

Speaker unclear

?Thank

Passages & reports (1)
  • Thank

Speaker 0

you. We'll go next now to Casey Woodring with JP Morgan.

Passages & reports (1)
  • you. We'll go next now to Casey Woodring with JP Morgan.

Speaker unclear

?Great. Thanks for squeezing me in.

Passages & reports (1)
  • Great. Thanks for squeezing me in.

Speaker 5

Um ?I guess my first ?one is

Passages & reports (5)
  • Um
  • I
  • guess my first
  • one
  • is

Speaker unclear

?just on

Passages & reports (1)
  • just on

Speaker 6

um capacity expansion. Uh ?just you know, given the anticipated increased demand from AI, I'm wondering how you're thinking ?about expanding capacity and what ?your utilization is currently.

Passages & reports (7)
  • um capacity expansion. Uh
  • just you know,
  • given the anticipated increased demand from AI, I'm wondering how you're thinking
  • about
  • expanding capacity and what
  • your
  • utilization is currently.

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 2

Cassie. Um so currently we have a a good amount ?of capacity available for our in VA work. So and the reason for that obviously is the volume declines that we've seen in the in the past years

Passages & reports (3)
  • Cassie. Um so currently we have a a good amount
  • of
  • capacity available for our in VA work. So and the reason for that obviously is the volume …

Speaker 5

and when um we went into those volume declines we did have um adequate space for a little bit of growth. So um we're comfortable

Passages & reports (1)
  • and when um we went into those volume declines we did have um adequate space for a little …

Speaker 2

with that for um at least ?a couple of years. Hard to say, obviously it depends on the growth rate and the mix and uh geography. But um and if that changes or when that changes, I should say it it will change obviously. Um then we have uh some space at our sites that we can expand in. So we are we're well set.

We have some empty um uh expansion space that we can convert relatively quickly and we watch this um literally months to months to months to make sure that we're um on top of it that we don't miss that window. Um but that speaks to the um
the the way we have expanded over the uh last few years in increments, small steps, a few more rooms here, a few more rooms there.

It is the best way for us and the best discipline for us to expand. From our bioanalytical capacity,
we are, as I said, currently expanding because we have seen growth over the last few years in that space when in Vivo work actually declined. And we see this as a higher growth area going forward. So those five expansions that are currently underway will give us that necessary capacity that we're looking for.

So this is an always always. We're very disciplined about the capacity expansion, trying to always have enough space but not to be too far ahead.

Passages & reports (7)
  • with that for um at least
  • a
  • couple of years. Hard to say, obviously it depends on the growth rate and the mix and uh g…
  • we're well set. We have some empty um uh expansion space that we can convert relatively qu…
  • the the way we have expanded over the uh last few years in increments, small steps, a few …
  • we are, as I said, currently expanding because we have seen growth over the last few years…
  • necessary capacity that we're looking for. So this is an always always. We're very discipl…

Speaker unclear

?Got

Passages & reports (1)
  • Got

Speaker 0

it.

Passages & reports (1)
  • it.

Speaker unclear

?That's helpful.

Passages & reports (1)
  • That's helpful.

Speaker 7

And maybe just ?two quick ones as follow ups. The first is just would you expect um seasonal trends from three Q to 4Q in bookings to uh hold uh you know this year in terms of that you know normal step up in bookings you see in four Q. And then um just as backlog goes up, how should we expect um burn rate to trend kind of into twenty-seven?

Should we expect that to tick down? Thank

Passages & reports (4)
  • And maybe just
  • two quick
  • ones as follow ups. The first is just would you expect um seasonal trends from three Q to …
  • we expect um burn rate to trend kind of into twenty-seven? Should we expect that to tick d…

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 2

Yeah, so from a uh seasonal trend, uh so we do often see um uh higher bookings in Q4, particularly compared to uh to

Passages & reports (1)
  • Yeah, so from a uh seasonal trend, uh so we do often see um uh higher bookings in Q4, part…

Speaker 5

Q3 bookings, which is the summer ones, which is often has a little bit of a seasonality in there. Um and we have but it depends a little bit on the on the business that we have too. So and where um some of our global biopharmaceutical clients

Passages & reports (1)
  • Q3 bookings, which is the summer ones, which is often has a little bit of a seasonality in…

Speaker 2

are in terms

Passages & reports (1)
  • are in terms

Speaker unclear

?of

Passages & reports (1)
  • of

Speaker 5

uh finishing up

Passages & reports (1)
  • uh finishing up

Speaker 2

their budgets and are ready to uh prioritize the programs that are coming in. So overall um yeah we might see that. Um and as I said we're or net boot to build particularly is nonlinear. We we see quarter over quarter um changes and um and then it also depends obviously on the revenue base that we're seeing, but uh overall um should be should be seeing strong demand uh going forward.

We're we do see maybe to point out healthy proposal levels. Um we are the fifth uh consecutive quarter with increasing
proposal levels ?now, and that is certainly a good metric for us. Um particular w um was capture rates straying straying strong for us and um that should translate into good bookings. Great,

Passages & reports (5)
  • their budgets and are ready to uh prioritize the programs that are coming in. So overall u…
  • and um and then it also depends obviously on the revenue base that we're seeing, but uh ov…
  • proposal levels
  • now,
  • and that is certainly a good metric for us. Um particular w um was capture rates straying …

Speaker 0

thank

Passages & reports (1)
  • thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker unclear

?We'll

Passages & reports (1)
  • We'll

Speaker 0

go next now to Jared Haas with William Blair.

Passages & reports (1)
  • go next now to Jared Haas with William Blair.

Speaker unclear

?Hi,

Passages & reports (1)
  • Hi,

Speaker 3

uh

Passages & reports (1)
  • uh

Speaker unclear

?good morning.

Passages & reports (1)
  • good morning.

Speaker 5

Thanks for squeezing me in here. Um maybe I'll go back to I you know I appreciate some of the color you shared on you know examples of your modernization efforts and the work that you're doing around

Passages & reports (1)
  • Thanks for squeezing me in here. Um maybe I'll go back to I you know I appreciate some of …

Speaker 7

automation as part of the

Passages & reports (1)
  • automation as part of the

Speaker 5

long-term

Passages & reports (1)
  • long-term

Speaker 7

strategic goals. I guess I was just curious if there's any incremental call-outs in terms of opportunities or specific workflows that you point to that you think can move the needle either financially

Passages & reports (1)
  • strategic goals. I guess I was just curious if there's any incremental call-outs in terms …

Speaker 5

or operationally over the next handful of quarters. Yeah, actually, we

Passages & reports (1)
  • or operationally over the next handful of quarters. Yeah, actually, we

Speaker 2

pointed out a couple maybe from the prepared remarks that we felt are interesting examples. One is the automation of our production line for LAL reagents that increases 14% capacity for our production cap uh capacity for those reagents and also allows us to drive uh production with um basically fewer resources, so it will have an an impact on our

Passages & reports (2)
  • pointed out a couple maybe from the prepared remarks that we felt are interesting examples…
  • reagents and also allows us to drive uh production with um basically fewer resources, so i…

Speaker 5

um

Passages & reports (1)
  • um

Speaker 2

a positive impact

Passages & reports (1)
  • a positive impact

Speaker unclear

?on

Passages & reports (1)
  • on

Speaker 5

our material cost. Um another one is the Apollo

Passages & reports (1)
  • our material cost. Um another one is the Apollo

Speaker 2

Orchestrate. So Apollo is the platform that we use in all our businesses to communicate with our clients. And when I say communicate, it's that's where they see their samples that that are submitted, they see their test results, they see where their study is currently. And what we're going to do with Apollo Orchestrate in our biologics business is actually digitising the whole workflow from sample submission through the lab, scheduling, execution of the samples, test results back to the client.

That is another great example of how we're using modernization to create more efficiencies. We talked about the cost savings of three hundred million in the invest a day over the next few years, but also to
um improve our client centricity, make it easier for the clients to communicate with us and to see their test results, but then also make it easier for our employees to execute on the work.

So those are two great examples. And we have 500 initiatives
ongoing. Some are pretty complex and pretty impactful, and all of them will have some level of improvement. So I really look forward to the uh execution of those initiatives.

Passages & reports (5)
  • Orchestrate. So Apollo is the platform that we use in all our businesses to communicate wi…
  • currently. And what we're going to do with Apollo Orchestrate in our biologics business is…
  • test results back to the client. That is another great example of how we're using moderniz…
  • um improve our client centricity, make it easier for the clients to communicate with us an…
  • ongoing. Some are pretty complex and pretty impactful, and all of them will have some leve…

Speaker unclear

?Okay, got it. That's really

Passages & reports (1)
  • Okay, got it. That's really

Speaker 3

helpful. And then I also just

Passages & reports (1)
  • helpful. And then I also just

Speaker 5

wanted a clarification. When you talk about pricing and in sort of longer term, you know, you think about the lever there as sort of being the goal to cover the cost of inflation. Is that effectively a mechanical relationship where you could sort of benchmark price to a a specific measure of inflation or does it require a little bit more negotiation or or handholding

Passages & reports (2)
  • wanted a clarification. When you talk about pricing and in sort of longer term, you know, …
  • does it require a little bit more negotiation or or handholding

Speaker 7

with customers to

Passages & reports (1)
  • with customers to

Speaker unclear

?sort of be on

Passages & reports (1)
  • sort of be on

Speaker 5

the same page?

Passages & reports (1)
  • the same page?

Speaker 2

Yeah, so when we do proposals, um, they're a point in time for the most most of our customers and um it does require a m a a measure of negotiation and um you know making sure that you continue to win the work even so the price is slightly higher. So it we do have clients, some clients with rate cards where it is more automatic, but for the uh majority of our work it is an interaction with a client, um talking about the pricing, talking about uh the uh inflationary increases and how working with us will have um substantial benefits other than uh and not just uh a pricing benefit yes

Passages & reports (3)
  • Yeah, so when we do proposals, um, they're a point in time for the most most of our custom…
  • So it we do have clients, some clients with rate cards where it is more automatic, but for…
  • will have um substantial benefits other than uh and not just uh a pricing benefit yes

Speaker unclear

?thank

Passages & reports (1)
  • thank

Speaker 0

you we'll go next now to Eugene Park with Baird

Passages & reports (1)
  • you we'll go next now to Eugene Park with Baird

Speaker unclear

?Yep thanks for taking my question um just adding on to the the pricing questions,

Passages & reports (1)
  • Yep thanks for taking my question um just adding on to the the pricing questions,

Speaker 6

I noticed that pricing has yet to impact DSA revenue, but was there any impact

Passages & reports (1)
  • I noticed that pricing has yet to impact DSA revenue, but was there any impact

Speaker 2

on net bookings this quarter?

Passages & reports (1)
  • on net bookings this quarter?

Speaker 1

Yeah, no, I would just say uh on the whole, the answer is no. Um we're just now starting to see some discounting in the proposals. So, in terms of the bookings for Q3, the answer is no, we haven't seen that yet.

Passages & reports (1)
  • Yeah, no, I would just say uh on the whole, the answer is no. Um we're just now starting t…

Speaker unclear

?Got it,

Passages & reports (1)
  • Got it,

Speaker 4

makes sense.

Passages & reports (1)
  • makes sense.

Speaker unclear

?Thanks for that. And as a follow-up, um in RMS, what do you see on price increases

Passages & reports (1)
  • Thanks for that. And as a follow-up, um in RMS, what do you see on price increases

Speaker 6

for small models? Is that could that be a lever that can offset volume decline moving forward, or do we need government and academic end market to improve meaningfully?

Passages & reports (1)
  • for small models? Is that could that be a lever that can offset volume decline moving forw…

Speaker unclear

?Yeah, so um

Passages & reports (1)
  • Yeah, so um

Speaker 5

over the past um

Passages & reports (1)
  • over the past um

Speaker 2

we have always been able to use price to offset some of the volume declines in research models. Um as you know, research models volume has has declined for decades because of of the 3R initiatives that we as a company and the industry have initiated. So we will continue, we expect to continue to see price in research models. The level depends really on what we are going to see, as you said, in academic and government, and then also in some of our services areas.

So this was one of the first years where the pricing did not
offset the growth, the revenue growth or the the decline in in other areas, but it was less um the decline in research model volume versus a decline in the services. So what we want to see is a um return to growth in some of our services, such as cradle, um and and then we should see also some price

Passages & reports (4)
  • we have always been able to use price to offset some of the volume declines in research mo…
  • will continue, we expect to continue to see price in research models. The level depends re…
  • offset the growth, the revenue growth or the the decline in in other areas, but it was les…
  • such as cradle, um and and then we should see also some price

Speaker unclear

?here.

Passages & reports (1)
  • here.

Speaker unclear

?Thank

Passages & reports (1)
  • Thank

Speaker 0

you.

Passages & reports (1)
  • you.

Rayee of T D Cowan.

Passages & reports (1)
  • Rayee of T D Cowan.

Speaker unclear

?Uh

Passages & reports (1)
  • Uh

Speaker 6

yeah, thanks

Passages & reports (1)
  • yeah, thanks

Speaker unclear

?for

Passages & reports (1)
  • for

Speaker 3

squeezing me in.

Passages & reports (1)
  • squeezing me in.

Speaker unclear

?Um

Passages & reports (1)
  • Um

Speaker 6

maybe if I could just

Passages & reports (1)
  • maybe if I could just

Speaker 3

go back to sort of just looking at book to bill here in the quarter, ?uh on the slides, you know, it looks like three Q bookings doesn't include any adjustments. Uh we had the adjustment last quarter uh for the divestiture. Just is it is it right to think that three Q book to bill is sort of a clean number that doesn't

Passages & reports (3)
  • go back to sort of just looking at book to bill here in the quarter,
  • uh
  • on the slides, you know, it looks like three Q bookings doesn't include any adjustments. U…

Speaker unclear

?have any sort of headwinds from

Passages & reports (1)
  • have any sort of headwinds from

Speaker 3

the European ?uh discovery sale, and therefore is that sort of sort of the base bookings and sort of backlog number to think of going forward? ?And then as a follow-up, ?you know, you're expecting sort

Passages & reports (7)
  • the European
  • uh
  • discovery sale, and therefore is that sort of sort of the base bookings and sort of backlo…
  • And
  • then as a follow-up,
  • you know, you're
  • expecting sort

Speaker unclear

?of uh DSA rev growth of mid-single digits and 4Q. Is there

Passages & reports (1)
  • of uh DSA rev growth of mid-single digits and 4Q. Is there

Speaker 3

any reason why this level of growth shouldn't at least continue ?into 27 given sort of trailing 12

Passages & reports (3)
  • any reason why this level of growth shouldn't at least continue
  • into
  • 27 given sort of trailing 12

Speaker unclear

?month book to bills of 1.1? Thanks.

Passages & reports (1)
  • month book to bills of 1.1? Thanks.

Speaker 1

Yeah, uh relative to the divestiger question and the backlog, um the vestigers are no longer in the backlog numbers, so that's a clean number, so to speak. I would also just highlight, you know, we were really happy with the net book to bill number for Q3 at 109. It's seasonally usually a very weak quarter, and so it's a strong number, especially given the revenue outperformance.

Um, and if you look at the actual net bookings year over year for Q3, we're actually up 32%. So it was a really strong number. Um, you know, relative to how we see this mid single digit growth for Q4
being consistent with Q3 is kind of how we outlined the guidance. ?And then going into next year, I think we just have to look at a couple of things around some of the timing and mix of studies that could affect the growth rates for DSA.

We want to make sure we've got more visibility into the second half of 2027, and obviously having a few more
months under our belt will get us that visibility that we want to see for the second half of next year. ?And then finally, you know, we talked ?about the DSA growth all right now coming from volume. ?And with that volume ramp, we want to make sure we have availability of resources, and that's resources from the people side and ramping resources to support ?the studies that are needed and also the NHP piece of the supply chain.

So those are all things that we're working through. We don't want to comment too much more around
?the DSA growth rates for next year. But obviously, we're very encouraged by the strong netbook to bill numbers for the last four quarters, the proposal volumes, and it was great to see DSA return to mid-single digit growth here ?in the third quarter, and we expect to see it again in the fourth quarter.

Passages & reports (18)
  • Yeah, uh relative to the divestiger question and the backlog, um the vestigers are no long…
  • weak quarter, and so it's a strong number, especially given the revenue outperformance. Um…
  • being consistent with Q3 is kind of how we outlined the guidance.
  • And
  • then going into next year, I think we just have to look at a couple of things around some …
  • months under our belt will get us that visibility that we want to see for the second half …
  • And
  • then finally, you know, we talked
  • about
  • the DSA growth all right now coming from volume.
  • And
  • with that volume ramp, we want to make sure we have availability of resources, and that's …
  • the
  • studies that are needed and also the NHP piece of the supply chain. So those are all thing…
  • the
  • DSA growth rates for next year. But obviously, we're very encouraged by the strong netbook…
  • in
  • the third quarter, and we expect to see it again in the fourth quarter.

Speaker 3

Great, appreciate it. Thanks a lot for the comments. Thanks.

Passages & reports (1)
  • Great, appreciate it. Thanks a lot for the comments. Thanks.

Speaker unclear

?Thank

Passages & reports (1)
  • Thank

Speaker 0

you. At this time, Mr. Spencer, I'll turn things back to you, sir, for any closing comments.

Passages & reports (1)
  • you. At this time, Mr. Spencer, I'll turn things back to you, sir, for any closing comment…

Speaker 3

Great. Thank you, everyone, for joining the conference call this morning. This concludes the call. Thanks again.

Passages & reports (1)
  • Great. Thank you, everyone, for joining the conference call this morning. This concludes t…

Speaker 0

Thank you very much. Again, ladies and gentlemen, this does conclude Charles River Laboratory's third quarter 2026 earnings call. Thank you for your participation today. You may now disconnect.

Passages & reports (1)
  • Thank you very much. Again, ladies and gentlemen, this does conclude Charles River Laborat…
Source, accuracy & exportsMay contain errorsAccuracy unmeasured. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred.

Short unclear spans may appear inline between matching voice IDs. The ? marker retains unknown attribution; no voice identity is inferred for those words.

AI-generated transcript; names, numbers and wording may be inaccurate.

Speaker IDs are anonymous and local to this call. Section boundaries and timestamps are inferred.

The diarizer reached its eight-speaker limit; distinct voices may share an ID.

Zero-duration alignments: 0. Unassigned words: 241. No alignment has been repaired. Timestamps locate passages in the source recording; decimal positions do not establish word-level precision.

Official issuer source ↗ · Report an issue

Published transcript · Full recording available. Publication updated 2026-11-16T02:25:19.589Z.
Transcript version v1-01f1cb0d228236f5bfd2 · publication revision 1. Generated by AI; no listener-verified accuracy score is available.

Dotted spans marked ? have an unclear speaker. They remain unattributed even when shown inside a surrounding turn.

Copy or download
ReadableGrouped by speaker and paragraph with timestamps. Stored words unchanged.
As storedOne line per stored segment with its original speaker ID and start time. Exactly the stored words.
Official issuer source ↗Company overview ↗
TRANSCRIPT FEEDBACK

Report a passage

Your report is queued privately for review. It does not change this transcript automatically. Please avoid personal information.